A meta-analysis of 18FDG-PET-CT, 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer

European Journal of Radiology

Volumn 81, Issue 5, 2012, Pages 1007-1015

  Qu, Xinhua ^a,b   Huang, Xiaolu ^a   Yan, Weili ^c   Wu, Lianming ^c   Dai, Kerong ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Bone metastasis; Bone scintigraphy; Lung cancer; Magnetic resonance imaging; Meta analysis; Positron emission tomography; Positron emission tomography with computed tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; COCHRANE LIBRARY; CONTROLLED STUDY; DIAGNOSTIC VALUE; EMBASE; HUMAN; LUNG CANCER; MEDLINE; META ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RISK; SENSITIVITY AND SPECIFICITY; VALIDITY; BONE TUMOR; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; IMAGE SUBTRACTION; LUNG TUMOR; MALE; METASTASIS; PREVALENCE; REPRODUCIBILITY; REVIEW; STATISTICS;

BONE NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; POSITRON-EMISSION TOMOGRAPHY; PREVALENCE; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84859969041     PISSN: 0720048X     EISSN: 18727727     Source Type: Journal    
DOI: 10.1016/j.ejrad.2011.01.126     Document Type: Article

References (33)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108. (Pubitemid 40372904)
2. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97:59-69.
3. Schirrmeister H, Arslandemir C, Glatting G, et al. Omission of bone scanning according to staging guidelines leads to futile therapy in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2004;31:964-8. (Pubitemid 38915651)
4. D'Addario G, Früh M, Reck M, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl (5)):v116-9.
5. Schmidt GP, Reiser MF, Baur-Melnyk A. Whole-body MRIfor the staging and follow-up of patients with metastasis. Eur J Radiol 2009;70:393-400.
6. Fischer B, Lassen U, Mortensen J, et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 2009;361:32-9.
7. van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002;359:1388-93.
8. Berlin JA. Does blinding of readers affect the results of meta-analyses? university of Pennsylvania meta-analysis blinding study group. Lancet 1997;350:185-6. (Pubitemid 27303630)
9. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003;3:25.
10. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods 2006;11:193-206. (Pubitemid 44001277)
11. Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: dataanalytic approaches and some additional considerations. Stat Med 1993;12:1293-316. (Pubitemid 23230833)
12. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005;58:882-93. (Pubitemid 41115772)
13. Bury T, Barreto A, Daenen F, Barthelemy N, Ghaye B, Rigo P. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 1998;25:1244-7. (Pubitemid 28446049)
14. Earnest F, 4th, Ryu JH, Miller GM, et al. Suspected non-small cell lung cancer: incidence of occult brain and skeletal metastases and effectiveness of imaging for detection-pilot study. Radiology 1999;211:137-45. (Pubitemid 29161743)
15. Hsia TC, Shen YY, Yen RF, Kao CH, Changlai SP. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium -99m methylene diophosphate bone scan to detect bone metastases in patients with non-small cell lung cancer. Neoplasma 2002;49:267-71.
16. Gayed I, Vu T, Johnson M, Macapinlac H, Podoloff D. Comparison of bone and 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography in the evaluation of bony metastases in lung cancer. Mol Imaging Biol 2003;5: 26-31. (Pubitemid 36596542)
17. Cheran SK, Herndon 2nd JE, Patz Jr EF. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer 2004;44:317-25. (Pubitemid 38609440)
18. Ebert W, Muley T, Herb KP, Schmidt-Gayk H. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. Anticancer Res 2004;24:3193-201. (Pubitemid 39390972)
19. Erturan S, Yaman M, Aydin G, Uzel I, Müsellim B, Kaynak K. The role of wholebody bone scanning and clinical factors in detecting bone metastases in patients with non-small cell lung cancer. Chest 2005;127:449-54. (Pubitemid 40229302)
20. Fischer BM, Mortensen J, Langer SW, et al. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol 2007;18:338-45. (Pubitemid 46323103)
21. Ohno Y, Koyama H, Nogami M, et al. Whole-body MR imaging vs FDG-PET: comparison of accuracy of M-stage diagnosis for lung cancer patients. J Magn Reson Imaging 2007;26:498-509. (Pubitemid 350194569)
22. Ursavas A, Karadag M, Uzaslan E, et al. Can clinical factors be determinants of bone metastases in nonsmall cell lung cancer? Ann Thorac Med 2007;2: 9-13.
23. Heusner T, Gölitz P, Hamami M, et al. "One-stop-shop" staging: Should we prefer FDG-PET/CT or MRI for the detection of bone metastases? Eur J Radiol 2009;(November 26) [Epub ahead of print].
24. Krüger S, Buck AK, Mottaghy FM, et al. Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging 2009;36:1807-12.
25. Min JW, Um SW, Yim JJ, et al. The role of whole-body FDG PET/CT Tc 99m MDP bone scintigraphy, and serum alkaline phosphatase in detecting bone metastasis in patients with newly diagnosed lung cancer. J Korean Med Sci 2009;24:275-80.
26. Song JW, Oh YM, Shim TS, Kim WS, Ryu JS, Choi CM. Efficacy comparison between (18)F-FDG PET/CT and bone scintigraphy in detecting bony metastases of non-small-cell lung cancer. Lung Cancer 2009;65:333-8.
27. Takenaka D, Ohno Y, Matsumoto K, et al. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy. J Magn Reson Imaging 2009;30:298-308.
28. Liu N, Ma L, Zhou W, et al. Bone metastasis in patients with non-small cell lung cancer: the diagnostic role of F-18 FDG PET/CT. Eur J Radiol 2010;74:231-5.
29. Fogelman I, Cook G, Israel O, Van der Wall H. Positron emission tomography and bone metastases. Semin Nucl Med 2005;35:135-42. (Pubitemid 40568746)
30. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003;348:2500-7. (Pubitemid 36706537)
31. Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000;343:254-61. (Pubitemid 30490393)
32. van Westreenen HL, Westerterp M, Bossuyt PM, et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 2004;22:3805-12. (Pubitemid 41095222)
33. Bossuyt PM, Reitsma JB, Bruns DE, et al. The STARD statement for reporting studies of diagnostic accuracy: Explanation and elaboration. Clin Chem 2003;49:7-18. (Pubitemid 36078547)